Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Glimepiride | hsa00071 | Fatty acid degradation | 2.52E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | Glimepiride | hsa00500 | Starch and sucrose metabolism | 1.07E-03 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Glimepiride | hsa00630 | Glyoxylate and dicarboxylate metabolism | 4.12E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | | Glimepiride | hsa00730 | Thiamine metabolism | 8.96E-04 | 3 | Q9Y6K8, P05186, P24666 | AK5, ALPL, ACP1 | More | | Glimepiride | hsa00760 | Nicotinate and nicotinamide metabolism | 3.52E-02 | 1 | P21589 | NT5E | More | | Glimepiride | hsa00770 | Pantothenate and CoA biosynthesis | 2.27E-02 | 2 | O95498, O95497 | VNN2, VNN1 | More | | Glimepiride | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.77E-04 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | Glimepiride | hsa01100 | Metabolic pathways | 3.52E-02 | 23 | P05089, O95455, P21953, P32320, P11766, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, Q08477, P15907, Q9UNP4, P37837, P32321, Q9BPW9, Q9UHY7, P43490, P46976, P06737 | ARG1, TGDS, BCKDHB, CDA, ADH5, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, CYP4F3, ST6GAL1, ST3GAL5, TALDO1, DCTD, DHRS9, ENOPH1, PBEF1, GYG1, PYGL | More | | Glimepiride | hsa04060 | Cytokine-cytokine receptor interaction | 4.71E-02 | 2 | P78552, O75509 | IL13RA1, TNFRSF21 | More | | Glimepiride | hsa04072 | Phospholipase D signaling pathway | 9.70E-03 | 2 | Q92529, Q14344 | SHC3, GNA13 | More | | Glimepiride | hsa04150 | mTOR signaling pathway | 2.23E-02 | 3 | P42338, Q13322, P49841 | PIK3CB, GRB10, GSK3B | More | | Glimepiride | hsa04380 | Osteoclast differentiation | 4.80E-02 | 4 | P06239, P42338, P14778, Q8N149 | LCK, PIK3CB, IL1R1, LILRA2 | More | | Glimepiride | hsa04621 | NOD-like receptor signaling pathway | 1.93E-02 | 8 | Q16539, P10599, Q9H1Y0, P43490, O00463, P01375, P09341, P12838 | MAPK14, TXN, ATG5, PBEF1, TRAF5, TNF, CXCL1, DEFA4 | More | | Glimepiride | hsa04657 | IL-17 signaling pathway | 1.03E-02 | 6 | O00463, Q16539, P49841, P09341, P14780, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, TNF | More | | Glimepiride | hsa04659 | Th17 cell differentiation | 4.12E-02 | 4 | P06239, P14784, P14778, P07766 | LCK, IL2RB, IL1R1, CD3E | More | | Glimepiride | hsa04662 | B cell receptor signaling pathway | 7.25E-03 | 4 | P49841, P42338, P21854, Q8N149 | GSK3B, PIK3CB, CD72, LILRA2 | More | | Glimepiride | hsa04730 | Long-term depression | 3.52E-02 | 1 | Q14344 | GNA13 | More | | Glimepiride | hsa04750 | Inflammatory mediator regulation of TRP channels | 3.72E-02 | 3 | P14778, P42338, P24723 | IL1R1, PIK3CB, PRKCH | More | | Glimepiride | hsa04929 | GnRH secretion | 3.63E-02 | 2 | P42338, P49407 | PIK3CB, ARRB1 | More | | Glimepiride | hsa04960 | Aldosterone-regulated sodium reabsorption | 4.38E-02 | 1 | P48048 | KCNJ1 | More | | Glimepiride | hsa04973 | Carbohydrate digestion and absorption | 4.12E-03 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Glimepiride | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.27E-02 | 4 | Q16539, P09341, P25024, P25025 | MAPK14, CXCL1, CXCR1, CXCR2 | More | | Glimepiride | hsa05140 | Leishmaniasis | 2.47E-02 | 5 | P13612, O75015, P01375, P49006, Q16539 | ITGA4, FCGR3B, TNF, MARCKSL1, MAPK14 | More | | Glimepiride | hsa05146 | Amoebiasis | 4.20E-02 | 5 | P09341, P14778, P27930, P01375, P05089 | CXCL1, IL1R1, IL1R2, TNF, ARG1 | More | | Glimepiride | hsa05163 | Human cytomegalovirus infection | 3.28E-02 | 7 | P01375, P50151, P49841, P14778, P25025, Q16539, O00463 | TNF, GNG10, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5 | More | | Glimepiride | hsa05225 | Hepatocellular carcinoma | 1.85E-02 | 2 | Q92529, P51531 | SHC3, SMARCA2 | More | | Glimepiride | hsa05418 | Fluid shear stress and atherosclerosis | 2.43E-03 | 7 | Q16539, P42338, P10599, P14780, P01375, P14778, P27930 | MAPK14, PIK3CB, TXN, MMP9, TNF, IL1R1, IL1R2 | More | | |